Nothing too surprising given the evolving GT space. I actually think the market may be too harsh today especially since Hem B program has a good chance to be first to market.
Have to wonder at this valuation if basically getting a free shot on goal with Hem B program with decent shot of success and decent upside if it succeeds and not much downside if it fails (EV near zero). Part of me wants to consider a position and then if Hem B fails, take my lumps (hopefully small) and move on. No position right now but on my watchlist.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.